JP4927089B2 - 肝細胞の凍結保存 - Google Patents
肝細胞の凍結保存 Download PDFInfo
- Publication number
- JP4927089B2 JP4927089B2 JP2008541614A JP2008541614A JP4927089B2 JP 4927089 B2 JP4927089 B2 JP 4927089B2 JP 2008541614 A JP2008541614 A JP 2008541614A JP 2008541614 A JP2008541614 A JP 2008541614A JP 4927089 B2 JP4927089 B2 JP 4927089B2
- Authority
- JP
- Japan
- Prior art keywords
- substrate
- cells
- hepatocytes
- covered
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000005138 cryopreservation Methods 0.000 title claims abstract description 19
- 210000003494 hepatocyte Anatomy 0.000 title claims description 93
- 238000000034 method Methods 0.000 claims abstract description 52
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 103
- 239000000758 substrate Substances 0.000 claims description 75
- 239000002609 medium Substances 0.000 claims description 38
- 239000012595 freezing medium Substances 0.000 claims description 17
- 238000010257 thawing Methods 0.000 claims description 17
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 13
- 239000012894 fetal calf serum Substances 0.000 claims description 13
- 230000008014 freezing Effects 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 11
- 238000007710 freezing Methods 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000003860 storage Methods 0.000 claims description 9
- 230000001464 adherent effect Effects 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 238000010030 laminating Methods 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 230000007704 transition Effects 0.000 claims description 3
- 210000005228 liver tissue Anatomy 0.000 claims description 2
- 238000010899 nucleation Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 210000005229 liver cell Anatomy 0.000 abstract description 5
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 18
- 238000004113 cell culture Methods 0.000 description 12
- 239000000512 collagen gel Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 9
- 229960001225 rifampicin Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 229960003604 testosterone Drugs 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 230000033444 hydroxylation Effects 0.000 description 8
- 238000005805 hydroxylation reaction Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000006698 induction Effects 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 6
- 239000002356 single layer Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- KYGUQDTWUBBBSD-YIJWYKPTSA-N (8r,9s,10r,13s,14s,17s)-15,17-dihydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4O)O)[C@@H]4[C@@H]3CCC2=C1 KYGUQDTWUBBBSD-YIJWYKPTSA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- XSEGWEUVSZRCBC-QXROXWLYSA-N (6s,8r,9s,10r,13s,14s,17s)-6,17-dihydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3C[C@H](O)C2=C1 XSEGWEUVSZRCBC-QXROXWLYSA-N 0.000 description 1
- 241001417092 Macrouridae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004517 glycocalyx Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 150000003515 testosterones Chemical class 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000164 trypan blue assay Toxicity 0.000 description 1
- 239000012808 vapor phase Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0278—Physical preservation processes
- A01N1/0284—Temperature processes, i.e. using a designated change in temperature over time
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/0231—Chemically defined matrices, e.g. alginate gels, for immobilising, holding or storing cells, tissue or organs for preservation purposes; Chemically altering or fixing cells, tissue or organs, e.g. by cross-linking, for preservation purposes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Description
1.1 ヒト肝細胞の単離
提供者の了解を得て採取した、いずれにせよ外科的に除去される組織部分から、ヒト提供者の肝細胞を周知のように単離した。そのために組織を灌流し、その際肝細胞が組織塊から解離され、灌流液から得ることができた。回収した肝細胞の生存能をトリパンブルーアッセイにより決定した。その後の実験のために、70%以上のトリパンブルー排除を示す細胞調製物のみを使用した。
次の実験でマルチウェル・プレート即ち6ウェル・プレート(657 160型、Greiner Bio-One社)の形の細胞培養容器を使用した。プレートをとりわけラットの尾から単離した天然コラーゲンゲルで被覆した。代案として1型コラーゲンであらかじめ被覆したマルチウェル・プレート即ち6ウェル・プレート(657 950 CELLCOAT型、Greiner Bio-One社)を使用した。6ウェル・プレートのウェル当りの底面積は9.6cm2であった。
単離した肝細胞をマルチウェル・プレートに播種した。そのために懸濁液2mlにつき250〜300万個の生肝細胞を含む単離肝細胞の懸濁液を作製した。6ウェル・プレートのウェルごとに2mlのこの細胞懸濁液をピペットで注入した。従って細胞密度は細胞培養容器の面積1mm2につき生肝細胞2600〜3200個であった。
上清の吸引の後、ウェルごとに約1mlの温度37℃の培地1を加えた。次に細胞を再び培養器で標準条件下でさらに約1時間静置した。次に主に付着していない細胞を含む上清を完全に吸引して除いた。
実施例1により凍結し、−151℃で貯蔵した肝細胞培養物をin vitro試験で引き続き使用するために、4週間以下の貯蔵時間の後に解凍し、再培養した。
新たに単離した肝細胞の培養及び本発明に基づき凍結保存した肝細胞の培養で形態的に無傷の細胞を計数することによって、生存(生)細胞の数を決定した。その場合0.259mm2の大きさの基準面の写真を計数した。基準面に見出された無傷細胞の数から全細胞培養容器の無傷細胞の数を推定した(使用したウェル当り9.6cm2の面積を有する6ウェル・プレートでは補正係数3700となった)。
図1は、新たに単離し、コラーゲンゲル層の上に播種したヒト肝細胞の形態(図1A)、及び、凍結保存し、解凍し、7日間再培養した単離ヒト肝細胞の形態(図1B)を示す。再培養した凍結保存細胞は新たに単離した細胞と形態的にほとんど相違がない。
テストステロンの酵素水酸化の誘導は、肝細胞の代謝及び/又は酵素能力の優れた指標である。無傷の肝細胞ではこの反応の基礎代謝「基礎レベル」が存在し、その際ヒドロキシテストステロン(OHT)が生成される。無傷の細胞では酵素誘導によって生成率が増大する。従って培養した肝細胞でのOHTの生成の検出から、培養した肝細胞の酵素能力及び生理的機能が推定される。
本発明に基づき凍結保存して再培養した肝細胞、及び新たに調製して培養した肝細胞は同程度の酵素誘導性を示した。テストステロンの水酸化の誘導の平均値を次表に示す。
Claims (14)
- 凍結保存用肝細胞の調製方法において、
(a)基質を準備するステップ、
(b)単離した肝細胞を準備するステップ、
(c)基質の上に肝細胞を2〜4×103/mm2の密度で播種するステップ、
(d)細胞が基質に付着しうるように、細胞で覆われた基質を10〜180分静置するステップ、
(e)細胞で覆われた基質から付着していない細胞を洗浄するステップ、
(f)細胞で覆われた基質を最大180分まで静置するステップ、
(g)細胞で覆われた基質を凍結培地中で凍結するステップ
を含み、ステップ(a)及び(b)の後、ステップ(c)〜(g)を記載の順に行う、上記方法。 - 基質がコラーゲン基質である請求項1に記載の方法。
- ステップ(d)において30〜90分静置する請求項1又は2に記載の方法。
- ステップ(e)において培地を積層し、続いて細胞で覆われた基質の上の液状上清を吸引して除く請求項1〜3のいずれか1つに記載の方法。
- ステップ(f)において30〜180分静置する請求項1〜4のいずれか1つに記載の方法。
- ステップ(g)において0.5μl/mm2の量の凍結培地を加える請求項1〜5のいずれか1つに記載の方法。
- 凍結培地がウシ胎児血清(FCS)及びDMSOを含む請求項6に記載の方法。
- ステップ(g)において細胞で覆われた基質に凍結培地を積層し、0.5〜20℃/分の冷却速度で−80℃以下に制御された冷却を行うことによって凍結を行い、場合によっては相転移を補償する請求項1〜7のいずれか1つに記載の方法。
- 単離した肝細胞の貯蔵及び再培養方法において、
請求項1〜8のいずれか1つに記載の方法のステップ(a)〜(g)、続いて、
(h)凍結した、細胞で覆われた基質を貯蔵するステップ、
(i)凍結した、細胞で覆われた基質を解凍するステップ、
(j)細胞で覆われた基質から付着していない細胞を洗浄するステップ、
(k)解凍した、細胞で覆われた基質に第2の基質を積層するステップ、
(l)基質の間に埋め込まれた細胞を再培養するステップ
を含み、ステップ(h)〜(l)を記載の順に行う、上記方法。 - ステップ(h)において貯蔵を−150℃で行う請求項9に記載の方法。
- ステップ(i)において、細胞で覆われた基質に温かい培地を積層する請求項9又は10に記載の方法。
- ステップ(j)において、細胞で覆われた基質に培地を積層し、続いて細胞で覆われた基質の上の液状上清を吸引して除く請求項9〜11のいずれか1つに記載の方法。
- 請求項9〜12のいずれか1つに記載の方法のステップ(a)〜(l)を含む、単離肝細胞のサンドイッチ培養物の作製方法。
- ステップ(b)が、
(b1)動物又はヒトの生体から得られた肝組織を準備するステップ、
(b2)上記組織から肝細胞を単離するステップ
を含む請求項13に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005057106.9 | 2005-11-25 | ||
DE102005057106A DE102005057106A1 (de) | 2005-11-25 | 2005-11-25 | Kryokonservierung von Hepatocyten |
PCT/EP2006/010549 WO2007059855A1 (de) | 2005-11-25 | 2006-11-03 | Kryokonservierung von hepatocyten |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009517007A JP2009517007A (ja) | 2009-04-30 |
JP4927089B2 true JP4927089B2 (ja) | 2012-05-09 |
Family
ID=37636094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008541614A Expired - Fee Related JP4927089B2 (ja) | 2005-11-25 | 2006-11-03 | 肝細胞の凍結保存 |
Country Status (21)
Country | Link |
---|---|
US (1) | US20080280357A1 (ja) |
EP (1) | EP1956896B1 (ja) |
JP (1) | JP4927089B2 (ja) |
CN (1) | CN101312648B (ja) |
AT (1) | ATE519364T1 (ja) |
AU (1) | AU2006317162B2 (ja) |
BR (1) | BRPI0618988B1 (ja) |
CA (1) | CA2632247C (ja) |
CY (1) | CY1112746T1 (ja) |
DE (1) | DE102005057106A1 (ja) |
DK (1) | DK1956896T3 (ja) |
ES (1) | ES2369414T3 (ja) |
HK (1) | HK1118422A1 (ja) |
IL (1) | IL191268A (ja) |
NZ (1) | NZ568555A (ja) |
PL (1) | PL1956896T3 (ja) |
PT (1) | PT1956896E (ja) |
RU (1) | RU2432395C2 (ja) |
SI (1) | SI1956896T1 (ja) |
WO (1) | WO2007059855A1 (ja) |
ZA (1) | ZA200804245B (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2221362A1 (en) * | 2009-02-19 | 2010-08-25 | Naturin GmbH & Co | Method for the cryopreservation of cells, artificial cell constructs or three-dimensional complex tissues assemblies |
WO2011059547A2 (en) | 2009-10-30 | 2011-05-19 | Xenotech, Llc | Cryopreservation of cells and subcellular fractions |
EP2637711B1 (en) * | 2010-11-10 | 2024-03-27 | ProKidney | Injectable formulations for organ augmentation |
CN102172237B (zh) * | 2010-12-30 | 2013-05-22 | 北京民海生物科技有限公司 | 一种细胞冻存液及其制备方法和应用 |
US9078430B2 (en) * | 2012-09-18 | 2015-07-14 | Albert Li | Cell preparation method |
US10159244B2 (en) | 2015-02-27 | 2018-12-25 | Lonza Walkersville, Inc. | Method for pooling hepatocytes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795711A (en) * | 1996-04-04 | 1998-08-18 | Circe Biomedical, Inc. | Cryopreserved hepatocytes and high viability and metabolic activity |
-
2005
- 2005-11-25 DE DE102005057106A patent/DE102005057106A1/de not_active Ceased
-
2006
- 2006-11-03 BR BRPI0618988-1A patent/BRPI0618988B1/pt not_active IP Right Cessation
- 2006-11-03 CN CN2006800439811A patent/CN101312648B/zh not_active Expired - Fee Related
- 2006-11-03 CA CA2632247A patent/CA2632247C/en not_active Expired - Fee Related
- 2006-11-03 EP EP06818357A patent/EP1956896B1/de not_active Not-in-force
- 2006-11-03 US US12/094,335 patent/US20080280357A1/en not_active Abandoned
- 2006-11-03 SI SI200631124T patent/SI1956896T1/sl unknown
- 2006-11-03 PL PL06818357T patent/PL1956896T3/pl unknown
- 2006-11-03 PT PT06818357T patent/PT1956896E/pt unknown
- 2006-11-03 JP JP2008541614A patent/JP4927089B2/ja not_active Expired - Fee Related
- 2006-11-03 AU AU2006317162A patent/AU2006317162B2/en not_active Ceased
- 2006-11-03 NZ NZ568555A patent/NZ568555A/en not_active IP Right Cessation
- 2006-11-03 AT AT06818357T patent/ATE519364T1/de active
- 2006-11-03 ZA ZA200804245A patent/ZA200804245B/xx unknown
- 2006-11-03 DK DK06818357.3T patent/DK1956896T3/da active
- 2006-11-03 ES ES06818357T patent/ES2369414T3/es active Active
- 2006-11-03 WO PCT/EP2006/010549 patent/WO2007059855A1/de active Application Filing
- 2006-11-03 RU RU2008125854/10A patent/RU2432395C2/ru not_active IP Right Cessation
-
2008
- 2008-05-06 IL IL191268A patent/IL191268A/en not_active IP Right Cessation
- 2008-09-16 HK HK08110253.3A patent/HK1118422A1/xx not_active IP Right Cessation
-
2011
- 2011-10-03 CY CY20111100949T patent/CY1112746T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE102005057106A1 (de) | 2007-06-06 |
EP1956896B1 (de) | 2011-08-10 |
BRPI0618988B1 (pt) | 2018-03-20 |
ES2369414T3 (es) | 2011-11-30 |
JP2009517007A (ja) | 2009-04-30 |
WO2007059855A1 (de) | 2007-05-31 |
SI1956896T1 (sl) | 2011-11-30 |
AU2006317162B2 (en) | 2012-05-31 |
DK1956896T3 (da) | 2011-11-21 |
PL1956896T3 (pl) | 2011-12-30 |
CY1112746T1 (el) | 2016-02-10 |
CN101312648B (zh) | 2013-08-14 |
EP1956896A1 (de) | 2008-08-20 |
ATE519364T1 (de) | 2011-08-15 |
HK1118422A1 (en) | 2009-02-13 |
CA2632247C (en) | 2012-01-03 |
NZ568555A (en) | 2011-01-28 |
RU2432395C2 (ru) | 2011-10-27 |
US20080280357A1 (en) | 2008-11-13 |
CN101312648A (zh) | 2008-11-26 |
RU2008125854A (ru) | 2010-01-10 |
PT1956896E (pt) | 2011-10-31 |
CA2632247A1 (en) | 2007-05-31 |
IL191268A (en) | 2012-07-31 |
BRPI0618988A2 (pt) | 2011-09-20 |
ZA200804245B (en) | 2009-08-26 |
AU2006317162A1 (en) | 2007-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5271076B2 (ja) | 新規な細胞組成物およびその調製方法 | |
Reubinoff et al. | Effective cryopreservation of human embryonic stem cells by the open pulled straw vitrification method | |
JP4927089B2 (ja) | 肝細胞の凍結保存 | |
Sosef et al. | Cryopreservation of isolated primary rat hepatocytes: enhanced survival and long-term hepatospecific function | |
Li et al. | A simplified method for the culturing of primary adult rat and human hepatocytes as multicellular spheroids | |
JP2020000245A (ja) | シート状細胞培養物の製造方法 | |
EP3132023B1 (en) | Method of preparing cells for 3d tissue culture | |
CN109880791B (zh) | 一种肝纤维化类器官模型的体外构建方法 | |
Lloyd et al. | Cryopreservation of hepatocytes: a review of current methods for banking | |
JP2008546406A5 (ja) | ||
JP2007306856A (ja) | 細胞凍結保存方法 | |
Son et al. | Optimization of cryoprotectants for cryopreservation of rat hepatocyte | |
Lesman et al. | Cell tri-culture for cardiac vascularization | |
Sugimachi et al. | Long-term function of cryopreserved rat hepatocytes in a coculture system | |
Cruz Rodríguez et al. | Establishment of two dimensional (2D) and three-dimensional (3D) melanoma primary cultures as a tool for in vitro drug resistance studies | |
US10155928B2 (en) | Assays using a multi-divot platform and multi-source, multi-cell type clusters | |
Jonsson et al. | Improvement of cardiac efficacy and safety models in drug discovery by the use of stem cell-derived cardiomyocytes | |
Huang | Isolation of human placenta‐derived multipotent cells and in vitro differentiation into hepatocyte‐like cells | |
Mariana et al. | Hepatocytes isolation from adult rats for liver recellularization | |
Ehashi et al. | Three‐dimensional culture of porcine fetal liver cells for a bioartificial liver | |
Kluiver et al. | Long-term expansion of murine primary hepatocyte organoids | |
Giri et al. | Cryopreservation of primary porcine liver cells in an organotypical sandwich model in a clinically relevant flat membrane bioreactor | |
Francis | Integrins and vascular development in differentiated embryonic stem cells in vitro |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110531 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110728 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110913 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111129 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120117 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120208 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150217 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4927089 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |